Bristol Myers Squibb Company
NEWS
Bristol-Myers Squibb announced initial positive Phase III data, yet company shares dropped more than six percent.
There has been speculation for several years whether Pfizer Inc. would consider buying Bristol-Myers Squibb. That appears to have been laid to rest by comments made by Pfizer’s chief executive officer, Ian Read.
Bristol-Myers Squibb and the Harvard Fibrosis Network, part of the Harvard Stem Cell Institute, have launched a collaboration to discover and develop new therapies for fibrotic diseases.
The relationship between pharmaceutical companies and patient advocacy groups is long and deep and involves millions of dollars in donations, a new report reveals.
Investors in Ionis Pharmaceuticals are happy this morning after the company announced it struck another licensing deal with AstraZeneca that has the potential to yield up to $330 million.
Shares of Incyte Corporation are down more than 20 percent this morning after the company revealed that pairing is IDO1 drug in combination with Merck’s Keytruda failed to meet endpoints in a Phase III melanoma trial.
Eli Lilly and Company announced top-line data from its Phase III REACH-2 trial of Cyramza (ramucirumab) as a monotherapy second-line treatment for hepatocellular carcinoma (HCC), which is liver cancer.
The U.S. Food and Drug Administration (FDA) approved Mylan NV’s Symfi (efavirnenz, lamivudine and tenofovir disoproxil fumarate) for adult and pediatric HIV-1 patients.This marks the third HIV approval for the company.
Versant Ventures spinoff company Tempest Therapeutics secured $70 million in a Series B funding to advance the company’s immunotherapy pipeline.
JOBS
IN THE PRESS